Clinical Research Details

Clinical Research

A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesion (ABSORB III)

Study Description

The pivotal trial to support the US pre-market approval (PMA) of Absorb BVS. ABSORB III will evaluate the safety and effectiveness of the Absorb BVS System compared to the XIENCE in the treatment of subjects, including those with diabetes mellitus, with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.

Subjects will be randomized to treatment with the study device or an FDA approved stent.

Open Enrollment

Contact Name: Emily Green
Contact Phone: (904) 244-2794
Contact Email:


Principal Investigator
Theodore A. Bass, M.D.

Sub Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC

Sub Investigator
Martin "M" Zenni, M.D.